Novo Nordisk has had a tough year: a tumbling stock price resulting in the biggest leadership shakeup in the company’s 100-year history as investors turned thier back on the Danish drugmaker and its weight loss business.
It seemed investors had largely given up on Novo’s ability to translate its strides in pioneering GLP-1 drugs to financial gains as the lucrative market attracts new players. Scientists, however, say that the medicine still has potential.
What started with a focus on the drug’s ability to manage weight and blood sugar, and combat related conditions such as heart disease, is now expanding further with growing interest in how it might also impact the brain.
semaglutide, or as it is indeed better known, Ozempic and Wegovy, is a GLP-1 receptor agonist that was originally developed for diabetes patients to manage their blood sugar levels. However, it quickly became prescribed by doctors off-label en masse as its appetite surpressing and weight-loss properties became known. Today, it is approved for anti-obesity purposes and brings in billions annually for its maker, Novo Nordisk.Now, the medical community is discovering a growing list of added benefits from these drugs.
“Wegovy promotes weight loss and potentially other mechanisms not fully understood,” the U.S. Food and Drug Management wrote in a statement in August when it approved the drug for treating liver disease. Semaglutide is also cleared by regulators to reduce the risk of heart attacks and strokes in overweight peopel with cardiovascular disease, as well as to treat chronic kidney disease in diabetes patients.
Meanwhile, a rival drug by U.S. competitor Eli Lilly tirzepatide (known as Mounjaro and Zepbound), which also targets the GLP-1 hormone as well as another gut hormone called GIP, is approved for treating moderate to severe obstructive sleep apnea in adults with obesity.
But the benefits may not
Semaglutide shows promise in Alzheimer’s prevention, but Novo Nordisk stock struggles
Table of Contents
Recent trial data suggests that semaglutide, the active ingredient in weight loss drugs like Wegovy and Ozempic, may not be effective in treating dementia, but holds potential as a preventative therapy.
“It just gave a negative result as far as the drug is concerned in that particular population,” said Ivan Koychev, associate professor in neuropsychiatry at Imperial College London. Though, Koychev noted semaglutide does positively affect Alzheimer’s disease proteins, as evidenced by biomarker measures. “They’re impacting Alzheimer’s disease-linked proteins,they reduce their quantity in the cerebrospinal fluid,which suggests that it is indeed interacting directly with the alternative pathology.”
The trial also observed a reduction in systemic inflammation biomarkers. “The thinking is that it may be this anti-inflammatory effect that, if it is implemented early enough in the disease process, you can substantially modify the risk of dementia,” Koychev said. He emphasized, “The signal was always in the prevention space rather than the treatment space.”
Dr. David Nisenbaum echoed this sentiment, suggesting future research should focus on testing semaglutide and other GLP-1s earlier in the disease course as preventative measures. Novo Nordisk stated it is indeed reviewing the trial data but cautioned against premature speculation regarding semaglutide’s effect on dementia patients.
The science versus the Street
Despite the potential public health impact of Novo Nordisk’s innovations, the company’s stock has faced challenges over the past 18 months, leading to investor concern.
Novo shares are experiencing their worst year on record since listing on Nasdaq Copenhagen over three decades ago. After peaking at over 1,000 Danish kroner in mid-2024, the stock now trades around 320 kroner, representing a year-to-date drop of 50%.
This decline is driven by increased competition from U.S. rival Eli Lilly and the emergence of compounding pharmacies offering cheaper, copycat versions of semaglutide. Furthermore, investors are unconvinced the company’s pipeline will deliver significant financial returns amidst a growing number of hopeful market entrants.
Novo Nordisk Faces Headwinds and Opportunities in the Obesity Drug Market
Novo Nordisk, the Danish pharmaceutical giant behind the blockbuster weight-loss drugs Wegovy and Ozempic, is navigating a complex landscape of evolving market expectations, political pressure, and emerging competition. While the demand for obesity treatments remains high, factors like potential policy changes in the U.S. and the approval of new oral medications are creating both challenges and opportunities for the company.
The Impact of US Policy and Competition
Novo Nordisk’s success has not gone unnoticed. The potential for lower drug prices in the U.S., especially with the Inflation Reduction Act, and the possibility of import taxes, pose significant headwinds. These factors have led to a reassessment of near-term expectations for the company’s growth. Specifically, former President Donald Trump has publicly called for lower drug prices and has criticized pharmaceutical companies, potentially influencing future policy [https://www.cnbc.com/2025/11/06/trump-eli-lilly-novo-nordisk-deal-obesity-drug-prices.html].
Adding to the competitive pressure, Eli Lilly and other pharmaceutical companies are actively developing and marketing their own obesity treatments. Most recently, the FDA approved Lilly’s Zepbound for weight loss. Furthermore, Novo Nordisk itself faces a shift in the market with the recent approval of an oral version of Wegovy [https://www.cnbc.com/2025/12/22/fda-approves-first-glp-1-pill-for-obesity-from-novo-nordisk.html].
Analyst Outlook: Cautious Optimism
Despite these challenges, analysts at Goldman Sachs maintain a “Buy” rating for Novo Nordisk. While acknowledging that expectations have been adjusted downwards, they believe there is still potential for growth as the obesity market matures. They highlight the potential for Wegovy, CagriSema, and the newly approved oral Wegovy to drive value beyond current market expectations, though this will require time and evidence of increased prescriptions [https://www.cnbc.com/2025/11/06/trump-eli-lilly-novo-nordisk-deal-obesity-drug-prices.html].
Understanding GLP-1 Medications
Novo Nordisk’s success is rooted in its development of glucagon-like peptide-1 (GLP-1) receptor agonists. these medications, originally developed for type 2 diabetes, have been found to be highly effective in promoting weight loss.GLP-1s work by mimicking the effects of the naturally occurring GLP-1 hormone, which regulates appetite and blood sugar levels. They achieve this by:
* Increasing insulin release: Helping the body use glucose more effectively.
* Suppressing glucagon secretion: Reducing the liver’s production of glucose.
* Slowing gastric emptying: Making people feel fuller for longer.
* Reducing appetite: Directly impacting the brain’s hunger centers.
Wegovy and Ozempic are both GLP-1 receptor agonists, with Wegovy specifically approved for chronic weight management and Ozempic initially for type 2 diabetes. CagriSema is a newer, dual GLP-1 and GIP receptor agonist, showing even greater potential for weight loss in clinical trials.
The Future of Obesity Treatment
The obesity drug market is rapidly evolving. The introduction of oral GLP-1 medications like oral Wegovy represents a significant step forward, offering patients a more convenient administration method. However, the long-term impact of policy changes, increased competition, and the emergence of new therapies remains to be seen.
Key Takeaways:
* novo Nordisk faces headwinds from potential U.S. drug price regulations and increased competition.
* Analysts remain optimistic about the company’s long-term prospects, particularly with its pipeline of obesity treatments.
* GLP-1 medications are a groundbreaking approach to weight management, offering significant health benefits.
* The approval of oral Wegovy provides a more convenient option for patients.
Novo Nordisk will need to continue innovating and adapting to the changing market dynamics to maintain its leadership position in the rapidly growing obesity treatment sector. The company’s ability to navigate these challenges will be crucial for its future success and for improving the health of millions worldwide.